BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29940148)

  • 1. Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells.
    Qiu MJ; He XX; Bi NR; Wang MM; Xiong ZF; Yang SL
    Clin Chim Acta; 2018 Oct; 485():103-105. PubMed ID: 29940148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
    He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
    Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.
    Li S; Ji J; Zhang Z; Peng Q; Hao L; Guo Y; Zhou W; Cui Q; Shi X
    Mol Cell Biochem; 2020 Dec; 475(1-2):79-91. PubMed ID: 32761300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.
    Schonfeld M; Zhao J; Komatz A; Weinman SA; Tikhanovich I
    J Biol Chem; 2020 May; 295(20):7126-7137. PubMed ID: 32245889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
    Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
    Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment.
    Li TE; Wang S; Shen XT; Zhang Z; Chen M; Wang H; Zhu Y; Xu D; Hu BY; Wei R; Zheng Y; Dong QZ; Qin LX
    Front Immunol; 2020; 11():589997. PubMed ID: 33193421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-
    Shrestha R; Bridle KR; Crawford DHG; Jayachandran A
    Int J Med Sci; 2021; 18(12):2466-2479. PubMed ID: 34104078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
    Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
    Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
    Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
    Wan Y; Ge K; Zhou W; Lu J; Jia C; Zhu H
    Biol Chem; 2021 May; 402(6):729-737. PubMed ID: 33583159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells.
    Ke M; Zhang Z; Xu B; Zhao S; Ding Y; Wu X; Wu R; Lv Y; Dong J
    Int Immunopharmacol; 2019 Oct; 75():105824. PubMed ID: 31437792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
    Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
    Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
    Yang HY; Sun LJ; Mao YL
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.
    Kim AK; Gani F; Layman AJ; Besharati S; Zhu Q; Succaria F; Engle EL; Bhaijee F; Goggins MB; Llosa NJ; Pawlik TM; Yarchoan M; Jaffee EM; Simons HC; Taube JM; Anders RA
    Cancer Immunol Res; 2019 May; 7(5):805-812. PubMed ID: 30902819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.
    Suzuki H; Iwamoto H; Tanaka T; Sakaue T; Imamura Y; Masuda A; Nakamura T; Koga H; Hoshida Y; Kawaguchi T
    Hepatol Int; 2024 Apr; 18(2):610-622. PubMed ID: 37864726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.